Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

Tesamorelin: what the published research shows

A research summary of tesamorelin, a growth hormone-releasing hormone analogue, covering its identity, receptor pathway, and the clinical studies that have examined it in HIV-associated lipodystrophy, liver fat, physical

peptides-pro Editorial

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), also referred to as a GHRH analogue or growth hormone-releasing factor analogue. It is a 44-amino-acid peptide; the evidence block for this page does not provide its sequence, molecular formula, or molecular weight, so those identifiers are not stated here. The compound is supplied for laboratory research use only.

The work summarised below centres on the GHRH receptor pathway, through which GHRH analogues act on pituitary somatotroph cells to stimulate endogenous growth hormone secretion.

Research Studies

Tesamorelin and visceral adipose tissue in HIV-associated lipodystrophy

A systematic review and meta-analysis evaluated the efficacy and safety of tesamorelin in people living with HIV (PLWH) with lipodystrophy receiving combination antiretroviral therapy (CART) [3]. The review searched PubMed, ClinicalTrials.gov, and Scopus from inception to February 9, 2026, for randomised controlled trials and incorporated GRADE assessment [3]. A separate meta-analysis of randomised controlled trials examined body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin in HIV-associated lipodystrophy [10].

Tesamorelin and liver fat in adults with fatty liver disease

A randomised, double-blind, placebo-controlled Phase II study is evaluating whether daily subcutaneous tesamorelin reduces liver fat in adults with fatty liver disease [2]. Participants receive tesamorelin or matching placebo for 52 weeks, with standardised lifestyle counselling in both groups [2]. Liver fat is quantified by MRI-proton density fat fraction (MRI-PDFF), and key safety monitoring includes glucose metrics and IGF-1 [2].

Tesamorelin and liver fat and histology in HIV

Liver disease is one of the leading co-morbidities of HIV infection, and nonalcoholic fatty liver disease (NAFLD) is present in approximately 30–40% of patients with HIV infection [8]. Nonalcoholic steatohepatitis (NASH) is a more severe form of NAFLD in which increased liver fat is accompanied by inflammation, cellular damage, and fibrosis [8]. NAFLD is most prevalent in patients who also have increased visceral adiposity, and the investigators note that HIV-infected individuals with increased visceral adiposity generally have decreased growth hormone secretion [8]. Tesamorelin is a GHRH analogue that increases endogenous growth hormone [8].

Tesamorelin and physical function in HIV (TRIUMPH)

The Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH) study is a randomised controlled trial examining the combined effect of exercise and the GHRH analogue tesamorelin on physical function [1]. TRIUMPH is a two-site, double-blind, randomised trial of 100 sedentary older adults (aged 50–80 years) living with HIV who are frail or at risk for frailty and have excess abdominal adiposity [1]. Enrolled participants are randomised to receive tesamorelin or placebo as an adjunct to a home-based semisupervised exercise programme for 24 weeks, followed by a 24-week extension phase [1]. A related ClinicalTrials.gov record describes the goal of learning whether tesamorelin will improve physical function and muscle health in adults with HIV when combined with exercise [5]. People with HIV experience earlier impairments in physical function compared to people in the general population, and they exhibit an earlier presentation and more rapid development of frailty, a multisystemic syndrome of aging characterised by reduced activity, fatigue, slowness, weakness, and weight loss [5]. While exercise can improve physical function in people with HIV, it is less effective in doing so than in the general population and is difficult to sustain in the long term [5].

Tesamorelin and cognition in aging HIV-infected persons

A Phase II trial tested whether tesamorelin, in combination with a text-messaging application to help with motivation and adherence, would significantly improve memory and thinking in HIV [7].

Tesamorelin and functional outcomes after peripheral nerve injury

A clinical trial evaluated the efficacy of tesamorelin as a therapy for peripheral nerve injuries [6]. The investigators hypothesised that treatment with tesamorelin would result in faster and more substantial recovery of motor and sensory function following surgical repair of injured peripheral nerves [6]. Patients with upper extremity nerve injuries were randomly assigned to receive either tesamorelin treatment or no treatment, with assessments for nerve regeneration, muscle function, and sensation conducted every three months for a total of 12 months [6]. Outcomes in patients receiving tesamorelin were compared to those in the untreated group to determine effectiveness [6].

Tesamorelin formulations and bioequivalence in healthy participants

A study examined the bioequivalence of tesamorelin (EGRIFTA WR and EGRIFTA®) formulations in healthy participants [4]. The evidence block for this record does not provide further methodological detail or results, so no additional findings are reported here.

Tesamorelin and excess visceral abdominal fat: case reports

Two clinical cases highlighted distinct therapeutic pathways with tesamorelin and glucagon-like peptide-1 receptor agonists in people living with HIV who present with differing patterns of excess visceral abdominal fat [9]. Excess visceral abdominal fat is a prevalent metabolic complication among people living with HIV-1, occurring even in individuals with normal or mildly elevated body mass index, and this pattern of fat accumulation is associated with metabolic dysfunction, cardiovascular risk, and other outcomes [9].

Tesamorelin in the broader peptide-therapy literature

A structured narrative review summarised contemporary human and translational evidence (January 1, 2020 onwards) on injectable peptides in sports medicine, noting that clinical adoption has outpaced high-quality evidence and regulatory consensus [11]. A separate review examined the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, describing peptides as short chains of amino acids with a pharmacological niche between small-molecule drugs and large proteins, and noting that their use in sports medicine is rapidly expanding [12].

If you are reading this for personal health reasons

The material described on this page is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp